Chemoimmunotherapy Regimen Approved to Treat DLBCL

MONDAY, June 10, 2019 -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news